Hong Kong Blood Cancer Foundation

Recent papers from Hong Kong Blood Cancer Foundation

1. Survival outcomes of high and intermediate-risk hormone receptor (HR)-positive human epidermal growth receptor-2 (HER2)-negative early breast cancer patients (EBC) who did and did not receive (neo)adjuvant chemotherapy.Journal of Clinical Oncology · 2026
2. Abstract PS2-04-19: 10-year survival outcomes of early-staged breast cancer patients with intermediate- and high- risk hormone receptor-positive her2-negative diseaseClinical Cancer Research · 2026
3. Modifiable Risk Factors Including Self-Perceived Stress for Breast Cancer in Hong Kong: A Case-Control Study of 10 757 SubjectClinical Medicine Insights Oncology · 2025
4. Real-world first round results from a charity lung cancer screening program in East AsiaJournal of Thoracic Disease · 2024
5. Preoperative considerations and benefits of neoadjuvant chemotherapy: insights from a 12-year review of the Hong Kong Breast Cancer RegistryHong Kong Medical Journal · 2023
6. Poor health literacy associated with stronger perceived barriers to breast cancer screening and overestimated breast cancer riskFrontiers in Oncology · 2023
7. Socioeconomic Disparity in Breast Cancer Detection in Hong Kong – A High Income City: Retrospective Epidemiological Study Using the Breast Cancer RegistryPLoS ONE · 2014